Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging

Cancer Research

Volumn 75, Issue 1, 2015, Pages 51-61

  Kadayakkara, Deepak K ^a,b,c   Korrer, Michael J ^a,b,c   Bulte, Jeff W M ^a,b,c   Levitsky, Hyam I ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; GLUCOPYRANOSYL LIPID A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; EPITOPE; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BIOLUMINESCENCE IMAGING; CD8+ T LYMPHOCYTE; CELL COUNT; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TRANSPORT; FEMALE; FLOW CYTOMETRY; IMAGING; IMMUNE RESPONSE; LYMPH NODE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REJECTION; UPREGULATION; VACCINATION; AGONISTS; ANIMAL; C57BL MOUSE; HUMAN; IMMUNOLOGY; LUMINESCENCE; MELANOMA, EXPERIMENTAL; MULTIMODAL IMAGING; PROCEDURES; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; LYMPH NODES; MAGNETIC RESONANCE IMAGING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIMODAL IMAGING; TOLL-LIKE RECEPTOR 4;

EID: 84920660378     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0820     Document Type: Article

References (32)

1. Ahrens ET, Bulte JWM. Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol 2013;13:755-63.
2. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor-cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
3. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12:18-27.
4. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010;16:304-10.
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
6. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947-50.
7. Makkouk A, Abdelnoor AM. The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharm Immunot 2009;31:331-8.
8. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
9. Johnson DA. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem 2008;8:64-79.
10. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011;6:e16333.
11. Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone (R) adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009;27:5956-63.
12. Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res 2011;17:3984-92.
13. Martin-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J Exp Med 2003;198:615-21.
14. Long CM, van Laarhoven HWM, Bulte JWM, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res 2009;69:3180-7.
15. de Vries IJM, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-13.
16. Badr CE, Tannous BA. Bioluminescence imaging: progress and applications. Trends Biotechnol 2011;29:624-33.
17. Lee N, Kim H, Choi SH, Park M, Kim D, Kim HC, et al. Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. Proc Natl Acad Sci U S A 2011;108:2662-7.
18. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocytemacrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. HumGene Ther 1999;10:1983-91.
19. Sen D, Deerinck TJ, Ellisman MH, Parker I, Cahalan MD. Quantum dots for tracking dendritic cells and priming animmune response in vitro and in vivo. PLoS ONE 2008;3:e3290.
20. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol 2006;177:3369-79.
21. Angeli V, Ginhoux F, Llodra J, Quemeneur L, Frenette PS, Skobe M, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006;24:203-15.
22. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010;120:607-16.
23. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97.
24. Soderberg KA, Payne GW, Sato A, Medzhitov R, Segal SS, Iwasaki A. Innate control of adaptive immunity via remodeling of lymph node feed arteriole. Proc Natl Acad Sci U S A 2005;102:16315-20.
25. Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng LL, et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A. PLoS ONE 2012;7:e51618.
26. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006;25:153-62.
27. Kaufman HL, Ruby CE, Hughes T, Slingluff CL, Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014;2:11.
28. Dekaban GA, Hamilton AM, Fink CA, Au B, de Chickera SN, Ribot EJ, et al. Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5:469-83.
29. de Chickera S, Willert C, Mallet C, Foley R, Foster P, Dekaban GA. Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. Int Immunol 2012;24:29-41.
30. Zhang X, de Chickera SN, Willert C, Economopoulos V, Noad J, Rohani R, et al. Cellular magnetic resonance imaging of monocyte-derived dendritic cell migration from healthy donors and cancer patients as assessed in a scid mouse model. Cytotherapy 2011;13:1234-48.
31. Dekaban GA, Snir J, Shrum B, de Chickera S, Willert C, Merrill M, et al. Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI. J Immunother 2009;32:240-51.
32. Slingluff CL Jr, Yamshchikov GV, Hogan KT, Hibbitts SC, Petroni GR, Bissonette EA, et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol 2008;15:3538-49.